## VK-1727

Cat. No.:	HY-125471		
Molecular Formula:	C <sub>29</sub> H <sub>25</sub> NO <sub>4</sub>		
Molecular Weight:	451.51		
Target:	EBV		
Pathway:	Anti-infecti	on	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

### SOLVENT & SOLUBILITY

		Mass Solvent Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.2148 mL	11.0740 mL	22.1479 mL		
		5 mM	0.4430 mL	2.2148 mL	4.4296 mL		
		10 mM	0.2215 mL	1.1074 mL	2.2148 mL		
	Please refer to the sc	Please refer to the solubility information to select the appropriate solvent.					
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.54 mM); Clear solution; Need ultrasonic					
		2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.54 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIV		
Description		nall molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 oliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple
In Vitro		gnificantly decreases the total population of G2 cell in EBV+ cells <sup>[1]</sup> . Intly confirmed the accuracy of these methods. They are for reference only. EBV- B cell lines; EBV+ SLCLs
	Concentration:	25 μΜ

# Product Data Sheet

0

Incubation Time:	72 hours
Result:	Significantly decreased the total population of G2 cell in EBV+ cells (HC1-2, SMS1-3 and
	AMS1-4) and not observed on EBV- (Ramos and BJAB) B cells.

### REFERENCES

[1]. Monaco MCG, et al. EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls. Neurol Neuroimmunol Neuroinflamm. 2023 Aug 10;10(5):e200149.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA